Our expects few new products to emerge from a week pipeline for both acute and chronic heart failure. Sales in the seven major markets will be modest with all the new drugs being add-on therapies to current standard regimes. Significant unmet patients needs will remain in both acute and chronic heart failure.
Scope
Comprehensive analysis of the current acute and chronic heart failure pipeline detailing the broad of developmental classes. A detailed clinical and commercial assessment of all key emerging therapies. Epidemiological based sales forecasts for key late-stage developmental heart failure agents in the seven major markets to 2016.
Highlights
The heart failure market is relatively stable, with few drugs being launched in the past five years and many of those launched having significant safety or commercial viability issues. It is also a market with high unmet need waiting to be addressed. Patients with heart failure have a poor prognosis with half of all patients diagnosed with severe heart failure dying within four years. The R&D pipeline for heart failure is a Phase II-heavy, diverse range of novel agents, with 50% all of candidates being in Phase II trials.
Reasons to Purchase
Quantify the future drugs in the acute and chronic heart failure market. Identify licensing opportunities based on company portfolio and market needs. Assess the remaining market opportunity, where established therapies and other developmental compounds fail to address key unmet clinical needs.
